Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago. These figures ...

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

Here are some other stocks moving lower in pre-market trading.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 21 cents. The results missed Wall Street ...

Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...